Obinutuzumab

證據等級: L5

預測適應症: 3 個

Obinutuzumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma

One-Sentence Summary

Obinutuzumab is a glycoengineered anti-CD20 monoclonal antibody originally established for chronic lymphocytic leukemia (CLL) treatment. The TxGNN model predicts it is effective for Follicular Lymphoma, a finding already substantiated by 10+ clinical trials (including 2 completed Phase 3 RCTs) and 10+ publications, indicating this signal largely reflects an already-established indication rather than a purely novel repurposing hypothesis. Note: this evidence pack also flags two additional CLL/SLL molecular-subtype predictions (pregerminal-center and IGHV-hypermutated) with comparably high model scores (~99.2%) but zero supporting trials or literature — these remain in Hold status and are not further developed below.

Quick Overview

Item	Content
Original Indication	Not on record in Norway market data (drug not marketed). Per clinical trial documentation (NCT02877550), obinutuzumab was originally approved for chronic lymphocytic leukemia (CLL) in combination with chlorambucil
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.18%
Evidence Level	L1
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in this evidence pack). Based on known clinical trial documentation, Obinutuzumab is a fully humanized, glycoengineered Type II anti-CD20 monoclonal antibody; its efficacy in CD20-positive B-cell malignancies such as CLL has been established, and mechanistically it is broadly applicable to other CD20-expressing B-cell cancers, including follicular lymphoma.

Obinutuzumab works by enhancing antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct B-cell killing of CD20-positive malignant cells — a mechanism shared across the B-cell lymphoma/leukemia disease family. Follicular lymphoma is a CD20-positive indolent B-cell lymphoma, so the mechanistic overlap with the drug's established CLL activity is strong. This is reinforced by the large, completed Phase 3 GALLIUM trial (NCT01332968, n=1,401), which demonstrated that obinutuzumab-based immunochemotherapy significantly prolonged progression-free survival compared with rituximab-based immunochemotherapy in previously untreated advanced follicular lymphoma — meaning this indication functions more as an already-validated use than a speculative new signal, and the TxGNN prediction here largely serves as model face-validation.

The original_indications field being empty in the source database is most likely a data-registration gap rather than evidence that the drug has no approved uses; obinutuzumab is a well-characterized, globally marketed biologic. By contrast, the two co-ranked CLL/SLL molecular-subtype predictions in this evidence pack (pregerminal-center IGHV-unmutated and IGHV-hypermutated subtypes) have no corresponding trials or literature at all, so their mechanistic plausibility (broad anti-CD20 activity in CLL/SLL) cannot currently be verified against real-world evidence and they remain purely model-driven (L5, Hold).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01332968	Phase 3	Completed	1401	GALLIUM: obinutuzumab + chemotherapy vs. rituximab + chemotherapy followed by maintenance in untreated advanced indolent NHL; established obinutuzumab superiority in PFS
NCT01059630	Phase 3	Completed	413	Bendamustine alone vs. bendamustine + obinutuzumab (GA101) in rituximab-refractory indolent NHL
NCT03332017	Phase 2	Completed	217	ROSEWOOD: zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in relapsed/refractory follicular lymphoma
NCT03817853	Phase 4	Completed	114	Safety of obinutuzumab short-duration (90-minute) infusion combined with chemotherapy in previously untreated advanced FL
NCT01582776	Phase 1/2	Completed	317	GALEN: obinutuzumab + lenalidomide in follicular and relapsed/refractory aggressive (DLBCL/MCL) B-cell lymphoma
NCT04034056	N/A (non-interventional)	Completed	299	Real-world effectiveness and safety of obinutuzumab in previously untreated advanced follicular lymphoma
NCT02611323	Phase 1/2	Completed	133	Obinutuzumab + polatuzumab vedotin + venetoclax in relapsed/refractory follicular lymphoma
NCT02600897	Phase 1/2	Completed	114	Obinutuzumab + polatuzumab vedotin + lenalidomide in relapsed/refractory follicular lymphoma
NCT03113422	Phase 2	Completed	56	Venetoclax + obinutuzumab + bendamustine as front-line therapy in high tumor-burden follicular lymphoma
NCT03341520	Phase 2	Completed	89	GAZAI: obinutuzumab + low-dose involved-site radiotherapy in early-stage nodal follicular lymphoma

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28976863	2017	RCT	NEJM	Primary GALLIUM report: obinutuzumab-based chemoimmunotherapy vs. rituximab-based in untreated advanced FL
29856692	2018	RCT	J Clin Oncol	GALLIUM sub-analysis: influence of chemotherapy backbone on obinutuzumab efficacy and safety
37506346	2023	RCT	J Clin Oncol	ROSEWOOD Phase 2: zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in relapsed/refractory FL
31296423	2019	RCT	Lancet Haematol	GALEN: obinutuzumab + lenalidomide in relapsed/refractory follicular B-cell lymphoma
37767550	2024	RCT	Haematologica	Polatuzumab vedotin + bendamustine/rituximab or obinutuzumab in relapsed/refractory FL (Phase Ib/II)
31360086	2017	Review	Blood Lymphat Cancer	Impact of obinutuzumab alone and in combination for follicular lymphoma
38660754	2024	Review	Turk J Haematol	Comprehensive review of FL management, including obinutuzumab-based regimens
39830356	2024	Review	Front Pharmacol	Rapid review of efficacy, safety, and cost-effectiveness of obinutuzumab in FL
28276536	2016	Review	Drugs Today	Overview of obinutuzumab's role in follicular lymphoma
35180337	2022	Review	Oncology	Follicular lymphoma: current and emerging therapies, including anti-CD20 antibodies

Norway Market Information

Currently no Norway market authorization on record. taiwan_regulatory.market_status for this candidate is reported as 未上市 (Not Marketed), with 0 registered authorizations and no license entries available for extraction.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunotherapy — anti-CD20 monoclonal antibody (glycoengineered Type II); not a conventional cytotoxic chemotherapeutic
Myelosuppression Risk	Not established in this dataset — please refer to the package insert warnings and precautions
Emetogenicity Classification	Not established in this dataset — please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions; as a monoclonal antibody biologic, it is not typically subject to conventional cytotoxic drug handling protocols, but this cannot be confirmed without label data

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all currently unavailable for this candidate — flagged as a Blocking-severity data gap pending TFDA/local package insert acquisition.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

The follicular lymphoma signal is backed by two completed Phase 3 RCTs (including the pivotal GALLIUM trial) and a broad base of Phase 1/2 combination-therapy data, meeting L1 evidence criteria — this is a well-established, not speculative, use of obinutuzumab. However, the absence of local (Norway) market authorization and package insert safety data prevents a full "Go" determination.

To proceed, the following is needed:

TFDA/local package insert data (key warnings, contraindications) — currently a Blocking-severity gap
Confirmed mechanism of action documentation from DrugBank or equivalent source
Clarification on Norway market/registration status, given the drug's established use elsewhere
Reconciliation of the original_indications field gap in the source database against known approved uses (e.g., CLL)
Continued monitoring for emerging trial/literature evidence on the two CLL/SLL molecular-subtype predictions (pregerminal-center and IGHV-hypermutated), both currently Hold/L5 with no supporting data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.